Maternal-Fetal Medicine · Preconception Counseling
Anticoagulation
Prior to & During Pregnancy
Preconception Discussion Series
Balancing maternal thrombotic risk · fetal teratogenicity · peripartum hemorrhage
Pathophysiology
Pregnancy: A Hypercoagulable State
5–10×
VTE risk increase
during pregnancy
15–20×
VTE risk increase
postpartum
3
Mechanisms:
↑ coagulation factors
↓ fibrinolysis · venous stasis
Postpartum carries the highest daily VTE risk of any period in a woman's life.
Preconception Framework
Multidisciplinary Planning Is Mandatory
🤰
Maternal-Fetal Medicine
Planning must occur prior to conception — not after a positive pregnancy test.
Risk Stratification · Prior VTE
Antepartum Prophylaxis: Who Needs It?
Antepartum Prophylaxis Required
- Single unprovoked prior VTE
- Hormone-associated VTE
- Homozygous Factor V Leiden
- Prothrombin gene mutation
- Antithrombin deficiency
Postpartum Prophylaxis Only
- VTE provoked by transient risk factor
- Non-hormonal trigger
- Risk factor fully resolved
- No severe thrombophilia
Risk stratification determines antepartum management. Individualize every case.
High-Risk Indication
Mechanical Heart Valves
-
⚠️
Exceptionally high thrombotic risk. Valve thrombosis peaks in the first trimester.
-
🔄
Peak risk driven by subtherapeutic transition from VKA to LMWH and fluctuating LMWH pharmacokinetics.
-
📋
Protocolized monitoring during medication transition is non-negotiable.
-
💊
Low-dose warfarin (≤5 mg/day) may continue only in select patients who understand teratogenic risk.
High-Risk Indication
Atrial Fibrillation & Cardiomyopathy
-
📊
Risk assessment via CHA₂DS₂-VASc score guides anticoagulation decisions.
-
🧠
Concurrent cardiomyopathy or heart failure: prioritize maternal stroke prevention.
-
🔀
VKAs and DOACs are typically substituted with LMWH during pregnancy.
Decisions are individualized — no single protocol applies to all AF patients.
Pharmacology · Agent Selection
Anticoagulant Safety in Pregnancy
| Agent |
Placental Transfer |
Fetal Safety |
Recommendation |
LMWH
Enoxaparin / Dalteparin |
None |
Safe; monitor maternal pharmacokinetics |
Agent of Choice |
UFH
Unfractionated Heparin |
None |
Safe; risk of maternal HIT & osteoporosis |
Secondary — Near Delivery |
VKA
Warfarin |
High |
Embryopathy, fetal bleeding, pregnancy loss |
Contraindicated (>6 wks) |
DOACs
Apixaban / Rivaroxaban |
High |
Fetal toxicity & embryopathy |
Absolute Contraindication |
| Fondaparinux |
Minimal / Unknown |
Insufficient human safety data |
HIT / Heparin Allergy Only |
Guideline-Directed Transitions
Discontinuing Teratogens
DOACs
- Switch to LMWH before conception
- Or immediately upon positive pregnancy test
- Early fetal ultrasound to confirm viability
- Document absence of embryopathy
VKAs (Warfarin)
- Substitute UFH or LMWH before 6 weeks
- Eliminates risk of warfarin embryopathy
- OR 2.26 for preterm birth with 1st-trimester exposure
- OR 3.78 for very preterm birth
The 6-week threshold for VKA cessation is critical. Transition must be planned preconceptionally.
Pharmacologic Management
LMWH Dosing Strategies
-
💉
ASH Guidelines: Standard prophylactic or intermediate (half-therapeutic) dosing for prior VTE patients.
-
📉
Pre- and postpartum LMWH meta-analyses confirm significant reduction in VTE recurrence vs. no prophylaxis.
-
🔬
Mechanical valve patients: dose-adjust via anti-Xa levels — plasma volume expansion and enhanced renal clearance alter pharmacokinetics.
-
📋
No large RCTs exist for mechanical valve management — consensus guidelines apply.
Peripartum Management
Bridging Strategy at Delivery
💉
36–37 Weeks
Convert therapeutic LMWH → IV UFH infusion
⏸️
≥24 hrs Before
Hold LMWH prior to scheduled induction or cesarean
🛑
4–6 hrs Before
Halt UFH infusion before delivery or neuraxial anesthesia
✅
Delivery
Anesthesia consultation mandatory for all anticoagulated patients
LMWH's long half-life precludes neuraxial anesthesia if administered too close to labor — epidural hematoma risk.
Postpartum Management
Resumption of Anticoagulation
12–24 h
After vaginal delivery
(assuming hemostasis)
24 h
After cesarean delivery
(assuming hemostasis)
4–6 wks
Postpartum prophylaxis
for prior VTE
Lactation safety: Warfarin and LMWH are safe during breastfeeding. DOACs currently lack definitive safety profiles for lactation.
Clinical Summary
Key Preconception Principles
-
🔴
DOACs: Absolute contraindication. Transition to LMWH before conception or at positive test.
-
🟡
VKAs: Discontinue before 6 weeks gestation. Exception: select mechanical valve patients (≤5 mg/day).
-
🟢
LMWH: Agent of choice throughout pregnancy. Monitor anti-Xa levels in high-risk patients.
-
🏥
Multidisciplinary planning (MFM, cardiology, hematology, anesthesia) must occur prior to conception.
-
📅
Postpartum: Resume anticoagulation within 12–24 hours. Continue prophylaxis 4–6 weeks for prior VTE.